Abstract: Disclosed is a complex of pea protein and proanthocyanidins for use in the treatment of disorders caused by alterations of the intestinal epithelial tissue.

Abstract: Disclosed is a complex of pea protein and proanthocyanidins for use in the treatment of disorders caused by alterations of the intestinal epithelial tissue.

Abstract: Disclosed is a complex of pea protein and proanthocyanidins for use in the treatment of disorders caused by alterations of the intestinal epithelial tissue.

Abstract: The invention generally relates to compositions comprising a soluble chitosan derivative and an H2 receptor antagonist, and the use of the compositions for treating skin or mucosal diseases, such as inflammatory diseases or infectious disease.

Abstract: Compositions for vaginal use comprising lupulus (Humulus lupulus) and an excipient base suitable for application in the vaginal and/or vulvar region, for the treatment of vaginal dryness (atrophic vaginitis) and of the disorders correlated thereto, pruritus, burning sensation, dryness, dyspareunia; they are also particularly useful for delaying and attenuating the changes in the physiological trophism of the vulvar and vaginal tissue and mucosa.

Abstract: Compositions for vaginal use comprising lupulus (Humulus lupulus) and an excipient base suitable for application in the vaginal and/or vulvar region, for the treatment of vaginal dryness (atrophic vaginitis) and of the disorders correlated thereto, pruritus, burning sensation, dryness, dyspareunia; they are also particularly useful for delaying and attenuating the changes in the physiological trophism of the vulvar and vaginal tissue and mucosa.

Abstract: The salt of diclofenac with a cyclic organic base is prepared by dissolving diclofenac in a suitable organic solvent, adding said cyclic organic base, reacting the two components together, removing the solvent and crystallizing the product obtained.Said salt is water soluble to an extent from 20% w/v to an extent exceeding 50% w/v, and is used to prepared pharmaceutical compositions preferably in granular form for use by dissolving in water for oral administration.

Abstract: New derivatives of 1,3-thiazolidin-4-yl carboxylic acid of the general formula I ##STR1## wherein R represents hydrogen, (C.sub.1 -.sub.4)alkyl, aralkyl, phenyl, phenyl substituted by a halogen atom or a methoxy group, formyl, acyl, trimethylsilyl;R' represents hydrogen, a pharmaceutically acceptable inorganic or organic cation, (C.sub.1 -.sub.4)alkyl, 2,2,2-trichloroethyl, acetonyl, benzyl, benzyl substituted by nitro or methoxy, phenyl, nitrophenyl, benzhydryl or trimethylsilyl;R' may also represent a radical capable of providing metabolic activation in vivo selected from acetoxymethyl, pivaloyloxymethyl, phthalidyl, benzoyloxymethyl, 5-indanyl, a group of formula ##STR2## or a group of formula ##STR3## in which R" stands for (C.sub.1 -.sub.4)alkyl, (C.sub.5 -.sub.6)cycloalkyl or aryl; A represents hydrogen, halogen, N.sub.3, OH, NH.sub.2 ; or a quaternary N-atom, particularly ##STR4## (and in this case R' is a negative charge; or a O--CO--NH.sub.

Abstract: New derivatives of 1,3-thiazolidin-4-yl carboxylic acid of the general formula I ##STR1## wherein: R represents hydrogen, (C.sub.1 -.sub.4)alkyl, aralkyl, phenyl, phenyl substituted by a halogen atom or a methoxy group, formyl, acyl, trimethylsilyl;R' represents hydrogen, a pharmaceutically acceptable inorganic or organic cation, (C.sub.1 -.sub.4)alkyl, 2,2,2-trichloroethyl, acetonyl, benzyl, benzyl substituted by nitro or methoxy, phenyl, nitrophenyl, benzhydryl or trimethylsilyl;R' may also represent a radical capable of providing metabolic activation in vivo selected from acetoxymethyl, pivaloyloxymethyl, phthalidyl, benzoyloxymethyl, 5-indanyl, a group of formula ##STR2## or a group of formula ##STR3## in which R" stands for (C.sub.1 -.sub.4)alkyl, (C.sub.5 -.sub.6)cycloalkyl or aryl; n may be zero or 1.The compounds possess antibacterial utility against microbial infections in man, animals and plants.

Abstract: New derivatives of 1,3-thiazolidin-4-yl carboxylic acid of the general formula I ##STR1## wherein: R represents hydrogen, (C.sub.1-4)alkyl,aralkyl, phenyl, phenyl substituted by a halogen atom or a methoxy group, formyl, acyl, trimethylsilyl;R' represents hydrogen, a pharmaceutically acceptable inorganic or organic cation, (C.sub.1-4)alkyl, 2,2,2-trichloroethyl, acetonly, benzyl, benzyl substituted by nitro or methoxy, phenyl, nitrophenyl, benzhydryl or trimethylsilyl;R' may also represent a radical capable of providing metabolic activation in vivo selected from acetoxymethyl, pivaloyloxymethyl, phthalidyl, benzoyloxymethyl, 5-indanyl, a group of formula ##STR2## or a group of formula ##STR3## in which R" stands for (C.sub.1-4)alkyl, (C.sub.5-6)cycloalkyl or aryl; A represents hydrogen, halogen, N.sub.3, OH, NH.sub.2 ; or a quaternary N-atom, particularly ##STR4## in this case R' is a negative charge); or a O--CO--NH.sub.2 group; or a group of the formula OR"', O--COR"', NH--CO--R"' or SR"', where R"' is (C.